Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 110,331

Document Document Title
WO/2015/200682A1
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurologica...  
WO/2015/192714A1
The present invention relates to a pyrroloimidazole ring derivative and a medical application thereof, and particularly to a pyrroloimidazole ring derivative represented by general formula (I) or a stereoisomer thereof, a pharmaceuticall...  
WO/2015/193667A1
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In particular, the disclosure relates to the use of CBD of t...  
WO/2015/193417A1
The present inventor has found that glioblastoma cells respond in unique ways to prolactin (PrI) receptor antagonists. The reaction of glioblastoma cells to treatment with PrI receptor antagonists is based on the presence and function of...  
WO/2015/193228A1
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...  
WO/2015/194564A1
 Provided are a composition, food, and drug for enhancing memorization learning function and/or cognitive function. Using a peptide including any one amino acid sequence of SEQ ID NOS: 1-16 as an active ingredient makes it possible to ...  
WO/2015/193255A1
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.  
WO/2015/192701A1
An amino pyranoid ring derivative represented by general formula (I), or stereoisomers, pharmaceutically acceptable salts, prodrugs, pharmaceutical compositions containing the derivative and medicinal use thereof in preparing dipeptidyl ...  
WO/2015/193219A1
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and...  
WO/2015/193457A1
The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord i...  
WO/2015/193217A1
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, 3,4-dihydropyrido[2,3-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, an...  
WO/2015/194928A1
The invention relates to the compounds 3-(1´,1´ -dimethylallyl)-herniarin (1) y 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) derived from coumarin, which have excellent antidepressant activity. The compound 3- (1,1´-dimethy...  
WO/2015/194926A1
Gabapentin and lysine clonixinate (CLG) can be combined to relieve neuropathic pain caused by both diabetic neuropathy and nerve injury. The CLG combination creates a synergy in the antiallodynic effect when the allodynia has been genera...  
WO/2015/195474A1
Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods for treating, preventing, or ameliorating one or more symptoms of an inflamm...  
WO/2015/192228A1
A composition comprising a Mixed Anthocyanin Formulation (MAF), wherin said MAF comprises four anthocyanidins/anthocyanins (e.g. kuromarin/cyanidin (Kur), oenin/malvidin (Oen), callistephin/pelargonidin (Cal), and peonidin (Peo) that inh...  
WO/2015/192772A1
A pharmaceutical application of an NMDA receptor antagonist. The NMDA receptor antagonist and a pharmaceutically acceptable salt or a pharmaceutical composition thereof are used to prepare drugs for treating or preventing central nervous...  
WO/2015/193668A1
The present disclosurerelates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering withetiologies that include: ...  
WO/2015/193229A1
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...  
WO/2015/192198A1
A method is described for treating a peroxisome biogenesis disorder by administering to an individual in need thereof an effective amount of an autophagy inhibitor. Uses, compositions, and commercial packages are also described. The pero...  
WO/2015/195880A1
The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2015/194494A1
The present invention addresses the problem of providing: a cell structure for use in the treatment of brain injury, which does not contain glutaraldehyde and can exert a sufficient therapeutic effect on brain injury; a method for produc...  
WO/2015/192804A1
A pharmaceutical composition for preventing and treating senile dementia and a preparation method therefor. The active ingredients of the pharmaceutical composition are prepared from the following raw materials in weight part: 20 to 50 p...  
WO/2015/194954A1
The present invention relates to a 6,7-dioxyalkyltetrahydroisoquinoline compound, or a salt or solvate thereof according to formula I: (formula I), (I) wherein R represents hydrogen or a fluorinated alkyl group, and R2 and R3 independent...  
WO/2015/190568A1
The present invention relates to a medicine for preventing and/or treating stress-induced diseases, said medicine being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[β-carboline-4,1'-...  
WO/2015/189778A1
The present invention relates to a new agomelatine composition, particularly agomelatine in solution which isadsorbed on an inert carrier or directly formulated. Another subject-matter of the invention is a solid form made of an agomelat...  
WO/2015/191745A1
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the...  
WO/2015/191726A1
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B', R1, R2, and R3 are described herein. The compounds are inhibitors to the ...  
WO/2015/188280A1
A method of treating or preventing depressed mood is describe, such as for treating or preventing postpartum blues or depression or other conditions associated with increased MAO-A levels. The method comprises administering to a subject ...  
WO/2015/191401A1
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various di...  
WO/2015/188368A1
Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence ar...  
WO/2015/191934A3
Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or trea...  
WO/2015/191707A3
Disclosed are particles comprising a complex of nicotine and cerium oxide and a biodegradable coating comprising agglutinin. Also disclosed is a method of treating or preventing neurodegenerative or neurological disorders in a mammal in ...  
WO/2015/191403A1
The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disor...  
WO/2015/190452A1
This invention addresses the problem of obtaining sake-yeast-containing tablets that exhibit sufficient tablet properties such as hardness and disintegrability even if each tablet contains a large amount of sake yeast. That is, this inve...  
WO/2015/191934A8
Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or trea...  
WO/2015/190564A1
 The present invention provides a compound having cholinergic muscarinic M1 receptor positive allosteric modulator activity, the compound being useful as a drug for the prevention, treatment, or the like of Alzheimer's disease, schizop...  
WO/2015/190555A1
 The present invention provides a synthetic peptide whereby antibodies to an autoantigen can be derived, and specifically provides: a multiplex alloantigenic peptide including a dendritic core and a B-cell-recognition peptide, the mult...  
WO/2015/192014A1
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kina...  
WO/2015/191743A1
The present application provides fee compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m', A', R1, R2, and R3 are described herein. The compounds are inhibitors t...  
WO/2015/189744A1
The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, ...  
WO/2015/190797A1
The present invention relates to a pharmaceutical composition for treating neurogenic bladder, containing oral mucosa stem cells as an active ingredient, to a method for treating neurogenic bladder using the pharmaceutical composition, a...  
WO/2015/190455A1
The present invention provides a tablet that contains a sake yeast and silicon dioxide; that contains, per tablet, at least 15 mass% of sake yeast cells (A); and that has a mass ratio (B/A), of the silicon dioxide (B) content to the sake...  
WO/2015/190568A9
The present invention relates to a medicine for preventing and/or treating stress-induced diseases, said medicine being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[β-carboline-4,1'-...  
WO/2015/186729A1
Provided are: an immediate-release tablet formulation that contains casein and/or casein hydrolysate at a high concentration as an active ingredient and yet has excellent mechanical strength; a composition for the immediate-release table...  
WO/2015/186128A1
The present invention disclosed methods of inducing maturation of oligodendrocyte cells. A method of inducing myelination in a patient suffering from demyelination is also disclosed  
WO/2015/188005A1
The invention relates to the preparation and characterization of novel salts of (R)-isometheptene and crystalline forms thereof; moreover, the invention describes the use of the novel salts alone or in combination with other therapeutic ...  
WO/2015/186056A1
The invention relates to compounds of formula (I) Formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-c...  
WO/2015/186134A1
Compounds, methods and uses of pseudo-trisaccharide aminoglycosides represented by the general formula I or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and a...  
WO/2015/184731A1
The invention provides fluoro-substituted chiral side chain-containing 2-arylbenzoheterocyclic compounds having affinity with Aβ plaque. The structural general formula of the compounds is shown as Formula (I), wherein X is N; Y is S or ...  
WO/2015/187845A1
Disclosed are chemical entities of formula (I) wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of form...  

Matches 351 - 400 out of 110,331